Fingerprint
Dive into the research topics of 'A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically